In the published article, there was an error in Figure 1 as published. The figure itself including the proportion of changes is correct. However, the numbers representing percent changes in reduction of symptoms do not correspond to those mentioned in the text but rather to a preliminary calculation from a smaller cohort of patients. Noteworthy, the improvement in abdominal symptoms assessed with the CFAbd-Score during ETI is in fact markedly higher in the now corrected version. The corrected Figure 1 and its caption appear below.
FIGURE 1
CFAbd-Score changes for the whole cohort and its 5 domains after therapy initiation (Table 1). Percent changes are calculated from estimated marginal means (EMMs) at week 24 of ETI therapy.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
gastrointestinal, patient reported outcome measure, CFTR modulators, elexacaftor, symptom score
Citation
Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D and Schwarz C (2023) Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score. Front. Pharmacol. 14:1207356. doi: 10.3389/fphar.2023.1207356
Received
17 April 2023
Accepted
21 April 2023
Published
03 May 2023
Volume
14 - 2023
Edited and reviewed by
Frederic Becq, University of Poitiers, France
Updates
Copyright
© 2023 Mainz, Zagoya, Polte, Naehrlich, Sasse, Eickmeier, Smaczny, Barucha, Bechinger, Duckstein, Kurzidim, Eschenhagen, Caley, Peckham and Schwarz.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jochen G. Mainz, j.mainz@klinikum-brandenburg.de
†These authors have contributed equally to this work
‡These authors share last authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.